Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has adjusted the confidentiality withholding deadline for disclosing its counterparty regarding a KRW 147.3B letter of intent (LOI) for a biopharmaceutical contract manufacturing agreement to May 31, 2024, following consultations with the client.
📊 [Key Disclosure Details & Financial Figures]
- Reason for Correction: Change in confidentiality withholding date following consultation with the customer
- Pre-correction Withholding Expiration Date: 2024-03-30
- Post-correction Withholding Expiration Date: 2024-05-31
- Subject: Execution of Letter of Intent (LOI) for Biopharmaceutical Contract Manufacturing Agreement
- Counterparty: U.S. pharmaceutical company (Withheld due to business confidentiality)
- Contract Value: KRW 147,284,499,200 (USD 112,534,000 / Applied Exchange Rate: USD/KRW 1,308.80)
- Ratio to Recent Annual Revenue: 4.91% (Recent Annual Revenue: KRW 3,001,295,197,683)
- LOI Execution Date: June 3, 2023
- Initial Disclosure Date: June 5, 2023
- Contract Period: From the execution date of the LOI to the execution date of the main contract
- Other Remarks: The contract value is legally binding between both parties; confirmed terms and counterparty details will be disclosed upon execution of the main contract
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Main Contract Execution and Counterparty Disclosure Following Expiration Date Change
This correction disclosure reports an adjustment of the confidentiality withholding deadline (from March 30, 2024 to May 31, 2024) for the biopharmaceutical contract manufacturing LOI signed with a U.S. pharmaceutical company in 2023. Tracking whether this letter of intent progresses into a definitive main contract and whether withheld counterparty details are unveiled upon the updated expiration date is essential to understand the progress of the transaction. Investors can verify subsequent developments through future correction disclosures or official Sales/Supply Contract Execution filings.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
